Patents by Inventor Barbara Wallner

Barbara Wallner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Salts of isophosphoramide mustard and analogs thereof
    Patent number: 9340563
    Abstract: Disclosed herein are crystalline compounds of formula (I) wherein A+ represents a hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: May 17, 2016
    Assignee: ZIOPHARM Oncology, Inc.
    Inventors: John C. Amedio, Jr., Barbara Wallner, Philip B. Komarnitsky
  • Salts of Isophosphoramide Mustard and Analogs Thereof
    Publication number: 20140194377
    Abstract: Disclosed herein are crystalline compounds of formula (I) wherein A+ represents a hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.
    Type: Application
    Filed: November 6, 2013
    Publication date: July 10, 2014
    Applicant: ZIOPHARM ONCOLOGY, INC.
    Inventors: John C. AMEDIO, JR., Barbara WALLNER, Philip B. KOMARNITSKY
  • PHARMACEUTICAL FORMULATIONS OF INDIBULIN AND USES THEREOF
    Publication number: 20140004192
    Abstract: The present invention relates to pharmaceutical formulations that increase the solubility and bioavailability of indibulin, such as a spray-dried solid dispersion of indibulin with at least one matrix polymer. The invention further provides dosage formulations comprising the dispersion and processes for making the dispersion. The present invention also discloses a method of treating immune system based disorders, hyper-proliferative disorders, angiogenesis, malignancies, and neoplasms with the indibulin formulations disclosed herein.
    Type: Application
    Filed: March 12, 2013
    Publication date: January 2, 2014
    Inventors: John C. Amedio, JR., Barbara Wallner, Marsha G. Marande
  • Combination Therapy With Organic Arsenicals
    Publication number: 20130261082
    Abstract: The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-I in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-I and another therapeutic agent.
    Type: Application
    Filed: March 6, 2013
    Publication date: October 3, 2013
    Applicant: ZIOPHARM ONCOLOGY, INC.
    Inventors: Barbara WALLNER, Philip B. KOMARNITSKY
  • Hematopoietic stimulation
    Publication number: 20070135354
    Abstract: Methods and products for stimulating hematopoietic, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and, mature blood cells are provided. The methods and products can be used both in vivo and in vitro.
    Type: Application
    Filed: June 26, 2006
    Publication date: June 14, 2007
    Applicant: Point Therapeutics, Inc.
    Inventors: Barbara Wallner, Barry Jones, Glenn Miller, Sharlene Adams
  • Anti-tumor agents
    Publication number: 20060287245
    Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
    Type: Application
    Filed: June 28, 2006
    Publication date: December 21, 2006
    Applicant: Point Therapeutics, Inc.
    Inventors: Barbara Wallner, Glenn Miller
  • Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
    Publication number: 20060084107
    Abstract: Methods of using inhibitors of the CD2/LFA-3 interaction-in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
    Type: Application
    Filed: November 18, 2005
    Publication date: April 20, 2006
    Inventors: Barbara Wallner, Kevin Cooper
  • Regulation of substrate activity
    Publication number: 20060052310
    Abstract: A method for regulating substrate activity in vivo is useful for the treatment of medical disorders such as inflammation, arteriolosclerosis and angiogenesis. The method involves the administration of an effective amount of a DPP-IV inhibitor to a patient in need of such treatment.
    Type: Application
    Filed: July 27, 2005
    Publication date: March 9, 2006
    Applicant: Point Therapeutics, Inc.
    Inventor: Barbara Wallner
  • Anti-tumor agents
    Publication number: 20050272703
    Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
    Type: Application
    Filed: May 17, 2005
    Publication date: December 8, 2005
    Applicant: Point Therapeutics, Inc.
    Inventors: Barbara Wallner, Glenn Miller
  • Anti-tumor agents
    Patent number: 6949514
    Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
    Type: Grant
    Filed: March 7, 2003
    Date of Patent: September 27, 2005
    Assignee: Point Therapeutics, Inc.
    Inventors: Barbara Wallner, Glenn Miller
  • Hematopoietic stimulation
    Publication number: 20050037976
    Abstract: Methods and products for stimulating hematopoietic, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and, mature blood cells are provided. The methods and products can be used both in vivo and in vitro.
    Type: Application
    Filed: June 28, 2004
    Publication date: February 17, 2005
    Applicant: Point Therapeutics, Inc.
    Inventors: Barbara Wallner, Barry Jones, Glenn Miller, Sharlene Adams
  • Stimulation of hematopoietic cells in vitro
    Publication number: 20040152192
    Abstract: Methods, compositions, and devices for stimulating the number and/or differentiation of hematopoietic cells in vitro are provided. The methods involve contacting the hematopoietic cells with an inhibitor of dipeptidyl peptidase (DPIV) in the absence of exogenously provided cytokines.
    Type: Application
    Filed: December 1, 2003
    Publication date: August 5, 2004
    Applicant: Point Therapeutics, Inc.
    Inventors: William Bachovchin, Barbara Wallner
  • Methods for expanding antigen-specific T cells
    Patent number: 6703238
    Abstract: Methods for expanding antigen-specific T cells in vitro are provided. The methods involve contacting hematopoietic precursor or progenitor cells with a heteroconjugate containing an inhibitor of dipeptidyl peptidase (DPIV) attached to an antigenic peptide, optionally with a culture step to expand T cells with a DPIV inhibitor. The culture may be performed in the absence of exogenously provided cytokines.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: March 9, 2004
    Assignee: Point Therapeutics, Inc.
    Inventors: William Bachovchin, Barbara Wallner
  • Anti-tumor agents
    Publication number: 20030158114
    Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
    Type: Application
    Filed: March 7, 2003
    Publication date: August 21, 2003
    Applicant: Point Therapeutics, Inc.
    Inventors: Barbara Wallner, Glenn Miller
  • Stimulation of hematopoietic cells in vitro
    Publication number: 20010018210
    Abstract: Methods, compositions, and devices for stimulating the number and/or differentiation of hematopoietic cells in vitro are provided. The methods involve contacting the hematopoietic cells with an inhibitor of dipeptidyl peptidase (DPIV) in the absence of exogenously provided cytokines.
    Type: Application
    Filed: March 20, 2001
    Publication date: August 30, 2001
    Inventors: William Bachovchin, Barbara Wallner
  • Stimulation of hematopoietic cells in vitro
    Patent number: 6258597
    Abstract: Methods, compositions, and devices for stimulating the number and/or differentiation of hematopoietic cells in vitro are provided. The methods involve contacting the hematopoietic cells with an inhibitor of dipeptidyl peptidase (DPIV) in the absence of exogenously provided cytokines.
    Type: Grant
    Filed: September 29, 1998
    Date of Patent: July 10, 2001
    Assignee: Point Therapeutics, Inc.
    Inventors: William Bachovchin, Barbara Wallner